

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

**INSIDE INFORMATION
APPROVAL TO COMMERCIALISE
PRESERVATIVE-FREE UNIT-DOSE SODIUM HYALURONATE
EYE DROPS (0.3%) IN THE PRC**

This announcement is made by Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company is pleased to announce that Guangdong Hanfeng Baisheng Pharmaceutical Company Limited, an indirect subsidiary of the Company, has obtained an approval from 國家藥品監督管理局 (National Medical Products Administration) for the registration and commercialisation of the preservative-free unit-dose Sodium Hyaluronate Eye Drops (0.3%) (the “**Approved Product**”) in the People’s Republic of China (the “**PRC**”, which for the purpose of this announcement, excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan).

The Approved Product is a preservative-free unit-dose eye drops containing 0.3% (0.4ml:1.2mg) sodium hyaluronate and is indicated for the treatment and symptomatic relief of various intrinsic ocular diseases, such as Sjögren's syndrome, Stevens-Johnson syndrome, dry eye syndrome, extrinsic ocular diseases and injuries caused by surgery, drugs, trauma and/or contact lens wearing. Other preservative-free unit-dose eye drops products of the Group are Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops (0.1%), Beifushu (rb-bFGF) Eye Drops, Moxifloxacin Hydrochloride Eye Drops and Diquafosol Sodium Eye Drops.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 13 September 2024

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Ms. Yeow Mee Mooi and Mr. Yan Man Sing Frankie.